SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the following upcoming March investor conferences: Leerink Healthcare Conference Date: March 9-11, 2026 Format: One-on-one meetings Location: Miami, FL Stifel 2026 Virtual CNS Fo
